BRISTOL-MYERS SQUIBB COMPANY Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $1.23 billion for the 3-month period ending 2011-12-31, per its 10-K filed 2012-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-12-31 was $1.23B, a 46.20% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-09-30 was $1.35B, a 4.07% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-06-30 was $1.31B, a 3.08% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-03-31 was $1.37B, a 24.16% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2011 was $5.26B, a 16.55% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2010 was $4.51B, a 2.10% increase from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2009 was $4.42B, a 19.91% increase from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2008 was $3.69B, a 79.63% increase from fiscal 2007.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2011-12-31 | $1.23B 10-K · filed 2012-02-17 | $2.59B derived: sum of 2 quarters · filed 2012-02-17 | $3.89B derived: sum of 3 quarters · filed 2012-02-17 | $5.26B 10-K · filed 2012-02-17 | ||
| 2011-09-30 | $1.35B 10-K · filed 2012-02-17 | $2.66B derived: sum of 2 quarters · filed 2012-02-17 | $4.03B derived: sum of 3 quarters · filed 2012-02-17 | $4.87B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2011-06-30 | $1.31B 10-K · filed 2012-02-17 | $2.67B derived: sum of 2 quarters · filed 2012-02-17 | $3.52B derived: sum of 3 quarters · filed 2012-02-17 | $4.82B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2011-03-31 | $1.37B 10-K · filed 2012-02-17 | $2.21B derived: sum of 2 quarters · filed 2012-02-17 | $3.51B derived: sum of 3 quarters · filed 2012-02-17 | $4.78B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2010-12-31 | $842.00M 10-K · filed 2012-02-17 | $2.14B derived: sum of 2 quarters · filed 2012-02-17 | $3.41B derived: sum of 3 quarters · filed 2012-02-17 | $4.51B 10-K · filed 2012-02-17 | ||
| 2010-09-30 | $1.30B 10-K · filed 2012-02-17 | $2.57B derived: sum of 2 quarters · filed 2012-02-17 | $3.67B 10-Q · filed 2010-10-26 | $4.80B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2010-06-30 | $1.27B 10-K · filed 2012-02-17 | $2.37B 10-Q · filed 2010-07-22 | $3.50B derived: sum of 3 quarters · filed 2012-02-17 | $4.70B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2010-03-31 | $1.10B 10-K · filed 2012-02-17 | $2.23B derived: sum of 2 quarters · filed 2012-02-17 | $3.43B derived: sum of 3 quarters · filed 2012-02-17 | $4.60B derived: sum of 4 quarters · filed 2012-02-17 | ||
| 2009-12-31 | $1.13B 10-K · filed 2011-02-18 | $2.33B derived: sum of 2 quarters · filed 2011-02-18 | $3.50B derived: sum of 3 quarters · filed 2011-02-18 | $4.42B 10-K · filed 2012-02-17 | ||
| 2009-09-30 | $1.20B 10-K · filed 2011-02-18 | $1.29B 10-Q · filed 2009-10-22 | $2.37B derived: sum of 2 quarters · filed 2011-02-18 | $3.29B 10-Q · filed 2010-10-26 | $3.51B 10-Q · filed 2009-10-22 | $4.29B derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | $1.17B 10-K · filed 2011-02-18 | $2.09B 10-Q · filed 2010-07-22 | $3.09B derived: sum of 3 quarters · filed 2011-02-18 | $3.94B derived: sum of 4 quarters · filed 2011-02-18 | ||
| 2009-03-31 | $920.00M 10-K · filed 2011-02-18 | $1.92B derived: sum of 2 quarters · filed 2011-02-18 | $2.77B derived: sum of 3 quarters · filed 2011-02-18 | |||
| 2008-12-31 | $999.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.85B derived: sum of 2 quarters · filed 2011-02-18 | $3.69B 10-K · filed 2011-02-18 | |||
| 2008-09-30 | $847.00M 10-Q · filed 2009-10-22 | $2.69B 10-Q · filed 2009-10-22 | ||||
| 2007-12-31 | $2.05B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |